TUNGKOL SA EPISODE NA ITO

Ingles
Estados Unidos

KOPYA NG SALIN 🔗

I-SEARCH ANG MGA NAKARAANG EPISODE

I-search ang mga nakaraang episode ng ASH 2014.

IBA PANG MGA EPISOD SA PODCAST NA ITO

Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.
Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv. The experts offer a comprehensive analysis of the curr…
Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma. “By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remis…
Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv. They debate the use of intensifie…
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.
Paunawa: Ang podcast at artwork na naka-embed sa page na ito ay mula sa ecancertv, na pag-aari ng may-ari nito at hindi kaakibat o ineendorso ng Listen Notes, Inc.